These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2258162)

  • 21. [Diagnosis and therapy of hepatorenal syndrome].
    Stremmel W; Strohmeyer G
    Schweiz Rundsch Med Prax; 1992 Jun; 81(24):806-8. PubMed ID: 1376484
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hepatorenal syndrome.
    Levy M
    Kidney Int; 1993 Mar; 43(3):737-53. PubMed ID: 8455374
    [No Abstract]   [Full Text] [Related]  

  • 23. Hepatorenal syndrome: definition, pathophysiology, clinical features and management.
    Bataller R; Sort P; Ginès P; Arroyo V
    Kidney Int Suppl; 1998 May; 66():S47-53. PubMed ID: 9573573
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hepatorenal syndrome].
    Detroz B; Honoré P; Monami B; Dewandre JM; Defraigne JO; Pirotte J; Beaujean MA; Meurisse M; Jacquet N
    Rev Med Liege; 1991 Apr; 46(4):188-95. PubMed ID: 2052812
    [No Abstract]   [Full Text] [Related]  

  • 25. [Physiopathology of refractory ascites and the hepatorenal syndrome].
    Arroyo V
    Nefrologia; 2002; 22 Suppl 5():41-6. PubMed ID: 12107916
    [No Abstract]   [Full Text] [Related]  

  • 26. Hepatorenal syndrome--is it central hypovolemia, a cardiac disease, or part of gradually developing multiorgan dysfunction?
    Lenz K
    Hepatology; 2005 Aug; 42(2):263-5. PubMed ID: 16025501
    [No Abstract]   [Full Text] [Related]  

  • 27. LEFT ventricular function assessed by echocardiography in cirrhosis: relationship to systemic hemodynamics and renal dysfunction.
    Nazar A; Guevara M; Sitges M; Terra C; Solà E; Guigou C; Arroyo V; Ginès P
    J Hepatol; 2013 Jan; 58(1):51-7. PubMed ID: 22989573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dopaminergic receptor-mediated effects in the mesenteric vasculature and renal vasculature of the chronically instrumented newborn piglet.
    Pearson RJ; Barrington KJ; Jirsch DW; Cheung PY
    Crit Care Med; 1996 Oct; 24(10):1706-12. PubMed ID: 8874310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Hepatorenal syndrome].
    Bosma JW; van Meyel JJ; Siegert CE
    Ned Tijdschr Geneeskd; 2010; 154():A1355. PubMed ID: 20456764
    [No Abstract]   [Full Text] [Related]  

  • 30. Amelioration of portal hypertension and the hyperdynamic circulatory syndrome in cirrhotic rats by neuropeptide Y via pronounced splanchnic vasoaction.
    Moleda L; Trebicka J; Dietrich P; Gäbele E; Hellerbrand C; Straub RH; Sauerbruch T; Schoelmerich J; Wiest R
    Gut; 2011 Aug; 60(8):1122-32. PubMed ID: 21317421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of hemodilution on splanchnic perfusion and hepatorenal function. II. Renal perfusion and hepatorenal function.
    Habler O; Kleen M; Hutter J; Podtschaske A; Tiede M; Kemming G; Corso C; Batra S; Keipert P; Faithfull S; Messmer K
    Eur J Med Res; 1997 Oct; 2(10):419-24. PubMed ID: 9348268
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of vasoconstrictors in patients with cirrhosis: type 1 HRS and beyond.
    Moreau R; Lebrec D
    Hepatology; 2006 Mar; 43(3):385-94. PubMed ID: 16496352
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pathogenetic factors and clinical elements in ascites and hepatorenal syndrome during liver cirrhosis.
    Gentilini P; Laffi G; La Villa G; Raggi VC
    Ann Ital Med Int; 1999; 14(4):264-84. PubMed ID: 10638019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathophysiology of the hepatorenal syndrome and potential for therapy.
    Levy M
    Am J Cardiol; 1987 Dec; 60(17):66I-72I. PubMed ID: 3687808
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatorenal syndrome: beyond liver failure.
    Fisher EM; Brown DK
    AACN Adv Crit Care; 2010; 21(2):165-86. PubMed ID: 20431446
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathophysiology, clinical features and management of hepatorenal syndrome.
    Garzia P; Ferri GM; Ilardi M; Messina FR; Amoroso A
    Eur Rev Med Pharmacol Sci; 1998; 2(5-6):181-4. PubMed ID: 10710816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cirrhosis: ascites and hepatorenal syndrome. Recent advances in pathogenesis.
    Henriksen JH
    J Hepatol; 1995; 23 Suppl 1():25-30. PubMed ID: 8551008
    [No Abstract]   [Full Text] [Related]  

  • 38. [Renal damage in liver cirrhosis: pathophysiology and management].
    Yamamoto T; Hishida A
    Nihon Rinsho; 1994 Jan; 52(1):159-64. PubMed ID: 8114286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyclooxygenase inhibition potentiates the renal vascular response to endothelin-1 in humans.
    Ahlborg G; Lundberg JM
    J Appl Physiol (1985); 1998 Nov; 85(5):1661-6. PubMed ID: 9804567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenesis of ascites formation and hepatorenal syndrome: humoral and hemodynamic factors.
    Ring-Larsen H; Henriksen JH
    Semin Liver Dis; 1986 Nov; 6(4):341-52. PubMed ID: 3544227
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.